De­fy­ing the odds, Pox­el plots a PhI­II course for its Type 2 di­a­betes med and shares surge on new da­ta

Pox­el is try­ing to mas­ter one of the tough­est acts in biotech: De­vel­op a new drug for Type 2 di­a­betes and win a reg­u­la­to­ry ap­proval — on its own.

It’s not easy, in the way that nav­i­gat­ing a mine field isn’t easy. But they are mov­ing ahead and say they have a very man­age­able game plan for get­ting through Phase III in Japan while look­ing for part­ners that can do much of the heavy lift­ing in Eu­rope and the US.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER